English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Mesoporous silica nanoparticles have drawn increasing attention as promising candidates in vaccine delivery. Previous studies evaluating silica-based vaccine delivery systems concentrated largely on macromolecular antigens, such as inactivated whole viruses. In this study, we synthesized dendritic mesoporous silica nanoparticles (DMSNs), and we evaluated their effectiveness as delivery platforms for peptide-based subunit vaccines. We encapsulated and tested  in vivo  an earlier reported foot-and-mouth disease virus (FMDV) peptide vaccine (B 2 T). The B 2 T@DMSNs formulation contained the peptide vaccine and the DMSNs without further need of other compounds neither adjuvants nor emulsions. We measured  in vitro  a sustained release up to 930 h. B 2 T@DMSNs-57 and B 2 T@DMSNs-156 released 23.7% (135 µg) and 22.8% (132 µg) of the total B 2 T. The formation of a corona of serum proteins around the DMSNs increased the B 2 T release up to 61% (348 µg/mg) and 80% (464 µg/mg) for B 2 T@DMSNs-57 and B 2 T@DMSNs-156.  In vitro  results point out to a longer sustained release, assisted by the formation of a protein corona around DMSNs, compared to the reference formulation (i.e., B 2 T emulsified in Montanide). We further confirmed  in vivo  immunogenicity of B 2 T@DMSNs in a particle size-dependent manner. Since B 2 T@DMSNs elicited specific immune responses in mice with high IgG production like the reference B 2 T@Montanide™, self-adjuvant properties of the DMSNs could be ascribed. Our results display DMSNs as efficacious nanocarriers for peptide-based vaccine administration.

In Vivo Sustained Release of Peptide Vaccine Mediated by Dendritic Mesoporous Silica Nanocarriers